KabuDo

NYSE: STE · Health Care Equipment

Steris

STERIS, an Irish-domiciled company based in Dublin, provides products and services that support patient care with an emphasis on infection prevention. FY2026 revenue was $5,936M: Healthcare $4,209M, Applied Sterilization Technologies $1,139M and Life Sciences $589M. Service and consumables were $4,684M of revenue. Net income rose to $782M. It has raised its dividend every year since 2005.

Last updated

Analysis last edited: November 6, 2026 · Financial data fetched: November 4, 2026 15:27 (SEC EDGAR) · Source 10-K filed: May 29, 2026

Built on10-K FY2026 · filed 2026-05-2910-Q (quarter ended 2026-09-30) · filed 2026-11-05Proxy statement (2026)

Next update expectedAfter FY2027’s 10-K is filed (roughly 60–90 days after fiscal year end (sooner for larger filers)), financials and analysis will be refreshed.

01

At a glanceFrom SEC data

Eight headline measures, each placed among the companies covered on this site.

Revenue growth
13.8%

Higher than 76% of 372 non-financial companies

Average yearly growth over the years shown

Operating margin
18.6%

Higher than 50% of 311 non-financial companies

Latest fiscal year (FY2026)

ROIC minus WACC
+2.0 pts

Higher than 45% of 311 non-financial companies

Return on capital above (or below) its estimated cost

Net debt ÷ EBITDA
0.9x

Higher than 35% of 304 non-financial companies

Below 0 means more cash than debt

Cash conversion
1.71x

Higher than 59% of 349 non-financial companies

Operating cash flow ÷ net income

Dividend raises
5 of 5

Years the dividend per share rose, of the last 5

P/E today
28.8x

Latest close 2026-11-04; trailing 12 months to 2026-09-30

Beta
0.55

Above 1 = moves more than the market

Each marker shows where this company sits among the non-financial companies covered on this site, not all listed companies (left = lowest, right = highest). A high position is not automatically good — for net debt ÷ EBITDA, higher means more debt. Details and formulas are in the sections below and in How to read this.

02

Valuation todayFrom SEC data

Price-based measures at the latest close, next to the same measures at the last fiscal year-end.

Share price$243.70close on 2026-11-04

Market cap$23.83B

P/E today
28.8x

At FY2026 year-end: 27.9x

Earnings: trailing 12 months to 2026-09-30

P/B today
3.3x

At FY2026 year-end: 3.0x

Book value at FY2026 year-end

EV/EBITDA today
15.9x

At FY2026 year-end: 14.6x

EBITDA for FY2026

FCF yield today
4.1%

At FY2026 year-end: 4.5%

Free cash flow for FY2026

Dividend yield today
1.0%

Dividends per share for FY2026

“Today” uses the latest closing price (2026-11-04, Yahoo Finance daily closing prices) and shares outstanding at the last fiscal year-end. The rest of this page — including the financial table and ROIC vs. WACC — uses fiscal year-end prices. These are reference figures, not a judgment of whether the stock is cheap or expensive.

03

What changed since last earningsFrom SEC data

The latest reported quarter against the same quarter a year earlier, the balance sheet against the previous quarter-end, and what management said in its latest earnings release.

Quarter ended Sep 30, 2026.

  • Revenue↑ +8.8%$1.46B → $1.59B (vs. a year earlier)
  • Operating margin↑ +0.3 pts18.2% → 18.5% (vs. a year earlier)
  • Net income↑ +11.4%$192M → $214M (vs. a year earlier)
  • Cash↑ +10.1%$482M → $531M (vs. previous quarter-end)
  • Long-term debt→ +0.0%$1.65B → $1.65B (vs. previous quarter-end)

Source: Form 10-Q ↗ (SEC XBRL). Long-term debt is the tagged long-term debt figure and leaves out short-term borrowings.

From the earnings release of Aug 5, 2026.

Management outlook → Reaffirmed

Reiterated fiscal 2027 revenue and earnings guidance. Source sentence
The Company is reiterating its prior guidance for revenue and earnings for fiscal 2027.

Key changes

  • Adjusted EPS of $11.10–$11.30. Source sentence
    Adjusted earnings per diluted share are anticipated to be in the range of $11.10 to $11.30, unchanged from prior expectations.
  • Q1 revenue up 7% to $1.5B. Source sentence
    Total revenue for the first quarter of fiscal 2027 increased 7% to $1.5 billion compared with $1.4 billion in the first quarter of fiscal 2026.

Written by AI. A line appears only if its figures and direction match the quoted sentence, which an automatic check confirms. Companies' outlooks are their own and may not be met. Read the release ↗

04

Company profileFrom SEC dataShow

Legal name
STERIS plc
Headquarters
DUBLIN, Ireland
Incorporated in
Ireland
Fiscal year end
03/31
Exchange & ticker
NYSE: STE
Industry
Health Care Equipment
CIK
1757898

Workforce (as of FY2026 year-end)

  • Employees

    18,000

Source: Form 10-K (FY2026) cover page and business description

05

Earnings calendarFrom SEC dataShow

When the company reports each quarter: the quarter-end date, the day results were released, and when the 10-Q or 10-K was filed.

Next report

Q3 FY2027

Quarter end: December 2026. In past years, Q3 results were released 35–38 days after quarter end (Feb 4, 2026; Feb 5, 2025; Feb 7, 2024). No date has been announced in the sources this site uses.

Reporting pattern

  • Fiscal year ends around March 31.
  • Reports four times a year: three quarterly reports (10-Q) and an annual report (10-K) for Q4.
  • Earnings releases came 35–44 days after quarter end over the last 12 quarters.
QuarterQuarter endedEarnings release (8-K)Report filed (10-Q / 10-K)
Q2 FY2027Sep 30, 2026Nov 4, 2026 (+35 days)Nov 5, 2026 10-Q (+36 days)
Q1 FY2027Jun 30, 2026Aug 5, 2026 (+36 days)Aug 7, 2026 10-Q (+38 days)
Q4 FY2026Mar 31, 2026May 11, 2026 (+41 days)May 29, 2026 10-K (+59 days)
Q3 FY2026Dec 31, 2025Feb 4, 2026 (+35 days)Feb 6, 2026 10-Q (+37 days)
Q2 FY2026Sep 30, 2025Nov 5, 2025 (+36 days)Nov 6, 2025 10-Q (+37 days)
Q1 FY2026Jun 30, 2025Aug 6, 2025 (+37 days)Aug 7, 2025 10-Q (+38 days)
Q4 FY2025Mar 31, 2025May 14, 2025 (+44 days)May 29, 2025 10-K (+59 days)
Q3 FY2025Dec 31, 2024Feb 5, 2025 (+36 days)Feb 7, 2025 10-Q (+38 days)
Q2 FY2025Sep 30, 2024Nov 6, 2024 (+37 days)Nov 7, 2024 10-Q (+38 days)
Q1 FY2025Jun 30, 2024Aug 6, 2024 (+37 days)Aug 8, 2024 10-Q (+39 days)
Q4 FY2024Mar 31, 2024May 8, 2024 (+38 days)May 29, 2024 10-K (+59 days)
Q3 FY2024Dec 31, 2023Feb 7, 2024 (+38 days)Feb 8, 2024 10-Q (+39 days)

Source: SEC EDGAR filing history. Release dates are the dates the earnings release was furnished to the SEC on Form 8-K (Item 2.02), which is normally the day results are announced. For a quarter whose 10-Q or 10-K isn’t filed yet, the date is the latest Item 2.02 8-K since the previous report, which may be a preliminary or other results-related update. Fiscal years are labeled by the calendar year in which they end.

06

Flagship products & servicesSite analysis

  • Healthcare

    Sterile processing and service

    Equipment, consumables and service for hospitals.

  • AST

    Contract sterilization

    Sterilization services for device makers.

  • Life Sciences

    Consumables and equipment

    Products for pharma manufacturers.

From the Form 10-K, FY2026, year ended 2026-03-31.

U.S. and worldwide share of flagship products/services

No market share figure is stated in the 10-K.

Reviewed: Form 10-K (FY2026, year ended 2026-03-31) · Form 10-Q (quarter ended 2026-06-30)

07

Recent strategic focusSite analysis

Recent developments.

  1. Q1 FY2027 results

    Revenue $1,493M (vs $1,391M); net income $200M (vs $177M).

    Source: Form 10-Q (quarter ended 2026-06-30)

  2. Consolidation plan

    Announced August 5, 2026; a new Center of Excellence in North Carolina.

    Source: Form 8-K (2026-08-05) — Item 2.05 consolidation plan

  3. EO settlements

    As of July 31, 2026, substantially all payments were made.

    Source: Form 10-Q (quarter ended 2026-06-30)

Capex ÷ D&A (FY2026)

0.76x

Below depreciation — investment is being pared back

formulacapital expenditures ÷ depreciation & amortization

e.g.$369M ÷ $487M = 0.76x

termsCapital expenditures (capex) · Depreciation & amortization (D&A)

R&D-to-revenue ratio (FY2026)

1.9%

formularesearch & development expense ÷ revenue × 100

e.g.$113M ÷ $5,936M × 100 = 1.9%

termsResearch & development (R&D) · Revenue (net sales)

M&A spend (6-year total)

$2.12B

Latest year: $20M

Cash-flow-statement spending on acquisitions, net of cash acquired

Where the money goes, over time

Unit: $M. Capex went from $239M in FY2021 to $369M in FY2026

  • Capex
  • R&D
  • M&A spend

formulacapital expenditures ÷ depreciation & amortization

termsCapital expenditures (capex) · Depreciation & amortization (D&A)

Source: each period's Form 10-K (SEC EDGAR). Latest: filed 2026-05-29

08

Key figures at a glanceFrom SEC data

FY2021–FY2026, 6 years.

Revenue (FY2026)

$5.94B

As reported in the 10-K

Revenue CAGR (5 years)

+13.8%▲favorable

formula(last-period revenue ÷ first-period revenue) ^ (1 ÷ years) − 1

e.g.($5,936M ÷ $3,108M) ^ (1÷5) − 1 = 13.8%

termsCAGR · ^ (exponent) · Revenue (net sales)

Operating margin (FY2026)

18.6%

+0.9pt vs. 5 years ago

formulaoperating income ÷ revenue × 100

e.g.$1,102M ÷ $5,936M × 100 = 18.6%

termsOperating income · Revenue (net sales)

ROE (FY2026)

11.3%▲favorable

6-year average: 7.3%

As reported in the 10-K

P/B (FY2026 end)

3.01x

formulafiscal year-end closing price ÷ book value per share

e.g.$221.13 ÷ $73.45 = 3.01x

termsP/B · BVPS

Period-end (fiscal year-end) value, not today's P/B

EV/EBITDA (FY2026 end)

14.6x

formula(market cap + interest-bearing debt − cash and equivalents) ÷ (operating income + depreciation & amortization)

e.g.($21,627M + $1,932M − $440M) ÷ ($1,102M + $487M) = 14.6x

termsEV/EBITDA · Market capitalization · Interest-bearing debt · EBITDA · Depreciation & amortization (D&A)

Period-end (fiscal year-end) value, not today's multiple

  • ▲

    Revenue grew +13.8% a year over 5 years (strong growth)

    From $3.11B in FY2021 to $5.94B in FY2026. The annualized rate (CAGR) makes it possible to compare growth pace across companies of different sizes.

  • ―

    Operating margin held roughly flat: 17.6% → 18.6%

    How much operating profit is left per $100 of revenue. It moved +0.9 points over 5 years — pricing power, cost control, and product mix all show up here.

  • ▲

    Equity ratio is 66.9% (a high level of financial stability)

    The share of total assets funded by equity rather than debt. 50%+ is often read as low bankruptcy risk, though the right level varies by industry (real estate and leasing run lower, for instance).

  • ▲

    Free cash flow was positive in 6 of 6 years

    Operating cash flow minus capital expenditures: the cash left over after funding the business’s own investment, available for dividends, buybacks, acquisitions, or debt paydown. A negative year can mean heavy investment, or weak core earnings — worth distinguishing.

  • ―

    ROE averaged 7.3% over 6 years (latest: 11.3%)

    How much profit was generated on shareholders’ equity. Roughly 10%+ is often cited as solid for a U.S. company, though this varies a lot by industry and capital intensity.

09

Business modelSite analysis

Sells capital equipment, consumables and service to hospitals and life science customers, and contract sterilization to device makers.

How money and goods flow at Steris
  1. 01 what it draws on

    Inputs & resources

    • About 18,000 employees (FY2026 average)
    • Manufacturing and sterilization facilities
    • Formulated chemistries
  2. 02 what it does

    Activities

    • Sterile processing equipment and consumables
    • Contract sterilization (AST)
    • Life sciences products and services
  3. 03 who it serves

    Customers

    • Hospitals and health systems
    • Medical device makers
    • Pharma and life science customers
  4. 04 how money comes in

    How it earns

    • Revenue $5,936M (FY2026)
    • Service $2,876M; consumables $1,808M; capital equipment $1,252M
    • No customer above 10% of a segment

How the business makes money

  • Dental was divested in fiscal 2025.
  • Service revenue rose 11.1%.
  • Debt down from $3,206M (FY2024) to $1,932M.

Government & regulation around the business

Non-market factors from the company’s filings: what governments and regulators fund, buy, set, approve or restrict, and which part of the flow above each one touches.

Products are regulated, and sterilization uses a regulated gas.

Revenue by segment (FY2026)

Unit: $M — bar length = revenue, (%) = share of total company revenue

  • Healthcare

    4,208.6 (71%)
  • Applied Sterilization Technologies

    1,138.5 (19%)
  • Life Sciences

    588.8 (10%)

Source: Form 10-K (FY2026, year ended 2026-03-31) Three reportable segments.

10

Contract structureSite analysisShow

Short-term or spot sales carry different earnings quality than long-term or auto-renewing contracts — this shows how the company actually contracts with its customers.

11

Customers & suppliersSite analysis

Who the company sells to and buys from. Companies rarely name either, so named counterparties come only from the company's own filings and press releases; otherwise this lists the concentration figures the 10-K discloses.

Customers

Hospitals, device makers and life science companies.

Named by the company

What the filings disclose

Suppliers

Not a material disclosure in the 10-K.

Named by the company

12

Competitors & peersSite analysis

Competitors the 10-K names, and the peer group the company itself chose in its proxy statement. Nothing here is this site's own pick.

The 10-K names Sterigenics in contract sterilization; others are unnamed.

Competitors named in the 10-K

Peer group the company chose

Peer group, from the proxy statement. Peers are companies the board considers comparable — for example when setting executive pay — not necessarily direct competitors.

Compensation peer group from the 2026 proxy statement.

Source: Proxy statement (2026)

Company names link to this site’s analysis where one exists; “site ↗” opens the company’s own website.

13

Six years of financialsFrom SEC data

Each chart's axis holds a single unit (never mixing dollars, %, and $/share). The table's per-period header links to the filing the numbers came from.

Revenue over time

Unit: $M

Source: each period's Form 10-K (SEC EDGAR). Latest: filed 2026-05-29

Profit over time (operating → net)

Unit: $M

  • Operating income
  • Pretax income
  • Net income

Source: each period's Form 10-K (SEC EDGAR). Latest: filed 2026-05-29

Margins over time

Unit: %

  • Operating margin
  • Net margin

formulaoperating income ÷ revenue × 100

termsOperating income · Revenue (net sales)

formulanet income attributable to the company ÷ revenue × 100

termsNet income (attributable to the company)

Cash flow over time

Unit: $M (below zero = cash went out)

  • Operating CF
  • Investing CF
  • Free CF

formulacash flow from operations − capital expenditures

termsFree cash flow (FCF) · Cash flow from operations (operating CF) · Capital expenditures (capex)

Source: each period's Form 10-K (SEC EDGAR). Latest: filed 2026-05-29

Financial stability & capital efficiency

Unit: %

  • Equity ratio
  • ROE

formulatotal equity ÷ total assets × 100 (as reported in the 10-K)

termsStockholders’ equity · Total assets

formulanet income ÷ average equity (beginning + ending, ÷2) × 100 (as reported in the 10-K)

termsNet income (attributable to the company) · Stockholders’ equity

Earnings per share (EPS) and dividend per share

Unit: $

  • EPS
  • Dividend per share

Source: each period's Form 10-K (SEC EDGAR). Latest: filed 2026-05-29

Line itemFY202110-K on EDGAR ↗FY202210-K on EDGAR ↗FY202310-K on EDGAR ↗FY202410-K on EDGAR ↗FY202510-K on EDGAR ↗FY202610-K on EDGAR ↗
Income statement ($M)
Revenue3,1084,2234,5365,1395,4605,936
Operating income5484787918368671,102
Pretax income5183676807037961,047
Net income (attributable)397244107378615782
Revenue growthcalc(this year’s revenue − last year’s revenue) ÷ last year’s revenue × 100—35.9%7.4%13.3%6.2%8.7%
Operating margincalcoperating income ÷ revenue × 10017.6%11.3%17.4%16.3%15.9%18.6%
Net margincalcnet income attributable to the company ÷ revenue × 10012.8%5.8%2.4%7.4%11.3%13.2%
Balance sheet ($M)
Total assets6,57411,42410,82211,06410,14710,737
Total equity3,8916,5456,0876,3156,6167,197
Interest-bearing debtSum of short- and long-term borrowings, notes/bonds payable1,6513,0883,0793,2062,0441,932
Equity ratio59.0%57.2%56.2%57.0%65.1%66.9%
ROE10.2%4.7%1.7%6.1%9.5%11.3%
Cash flow ($M)
Operating CF6906857579731,1481,341
Investing CF-1,154-667-383-887389-512
Financing CF346116-499-85-1,572-568
Free cash flowcalccash flow from operations − capital expenditures450397395613778972
Cash and equivalents221348208207172440
Per share & other
EPS ($)4.632.481.073.816.207.93
BVPS ($)45.4765.2861.6263.7367.1873.45
Dividend per share ($)1.571.691.842.032.232.46
Payout ratiocalcdividend per share ÷ diluted EPS × 10033.9%68.1%172.0%53.3%36.0%31.0%
P/E (x)41.197.5178.859.036.627.9
EV/EBITDA (x)calc(market cap + interest-bearing debt − cash and equivalents) ÷ (operating income + depreciation & amortization)23.026.116.218.018.014.6
P/B (x)calcfiscal year-end closing price ÷ book value per share4.193.703.103.533.373.01

P/B and EV/EBITDA use each period’s period-end (fiscal year-end) figures, not the current share price. Figures without a "calc" tag are as reported in the Form 10-K (the consolidated financial statements and, for older years, earlier 10-Ks), pulled automatically from SEC EDGAR. Where a later filing restated a prior period, the restated figure is used.

Last 8 quarters

Three-month figures from 10-Q filings. Change is versus the same quarter a year earlier. Newest quarter on top.

Quarter endedRevenueOperating incomeNet incomeDiluted EPS
2026-09-30$1.59B+8.8%$294M+10.7%$214M+11.4%—
2026-06-30$1.49B+7.3%$286M+16.2%$200M+12.8%—
2026-03-31 †$1.59B+7.3%$317M+46.6%$220M+51.1%—
2025-12-31$1.5B+9.2%$273M+11.4%$193M+11.2%$1.96
2025-09-30$1.46B$266M$192M$1.94
2025-06-30$1.39B$246M$177M$1.79
2025-03-31 †$1.48B$216M$146M—
2024-12-31$1.37B$245M$174M$1.75

† Fourth quarter = the 10-K’s annual figure minus the first three quarters; quarterly EPS isn’t derived this way because share counts change during the year.

14

Is ROIC above WACC?From SEC data

ROIC (the return on money invested in the business) above WACC (the cost of raising that money) means the company is creating value. WACC is an estimate, so its assumptions can be adjusted below.

ROIC (FY2026)

9.5%

formulaoperating income × (1 − tax rate) ÷ invested capital × 100 *invested capital = interest-bearing debt + total equity (average of beginning/ending)

e.g.$1,102M × (1 − 23.5%) ÷ $8,894M × 100 = 9.5%

termsOperating income · Effective tax rate · Invested capital · Interest-bearing debt · Total equity

WACC (this site’s estimate)

7.52%

formulacost of equity × equity weight + cost of debt × (1 − tax rate) × debt weight

e.g.Equity weight: $21.63B ÷ ($21.63B + $1.93B) = 91.8%

e.g.Debt weight: $1.93B ÷ ($21.63B + $1.93B) = 8.2%

e.g.WACC: 8.0% × 91.8% + 3.1% × (1 − 23.5%) × 8.2% = 7.52%

termsCost of equity · Equity weight (E/(D+E)) · Cost of debt · (1 − tax rate) · Debt weight (D/(D+E)) · Market capitalization

ROIC − WACC

+2.0pt▲favorable

Earning more than the cost of capital (ROIC > WACC in 2 of 6 years)

formulaROIC − WACC (positive means the business earns more than its cost of capital)

termsROIC · WACC

How firm is this? With the equity risk premium ±1 point and beta ±0.2, WACC runs 6.2%–9.2% and ROIC − WACC runs +0.3 to +3.3 points. The sign holds across this range. This describes the latest year and does not predict future value creation.

WACC 7.52% is this site’s estimate under the assumptions below (not a figure the company has published)

Risk-free rate
4.95% (10-year Treasury, 2026-11-03)
β
0.55 (price-derived adjusted beta, but correlation with the market is low (R² 0.05), so reliability is limited)
Equity risk premium
5.5%
Cost of equity
7.98%
Cost of debt
3.14%
Tax rate
23.5% (effective rate, FY2024–FY2026)
Capital structure (equity : debt)
92% : 8%
→ Change assumptions and recalculate

ROIC over time, vs. WACC

Unit: % — bars = each period's ROIC, horizontal line = latest WACC. Bars above the line are green, below are red

  • ROIC (above WACC)
  • ROIC (below WACC)
  • WACC 7.52%

formulaoperating income × (1 − tax rate) ÷ invested capital × 100 *invested capital = interest-bearing debt + total equity (average of beginning/ending)

termsOperating income · Effective tax rate · Invested capital · Interest-bearing debt · Total equity

formulacost of equity × equity weight + cost of debt × (1 − tax rate) × debt weight

termsCost of equity · Equity weight (E/(D+E)) · Cost of debt · (1 − tax rate) · Debt weight (D/(D+E)) · Market capitalization

Try different WACC assumptions

β and the equity risk premium are estimates with a real range of plausible values — move the sliders to check whether ROIC > WACC still holds. The risk-free rate starts at the 10-year Treasury yield on 2026-11-03 (U.S. Treasury).

Initial β: 0.55 (price-derived adjusted beta. Raw β 0.33, R² 0.05, 130 weeks)

formula0.67 × β + 0.33 (β = the slope of weekly stock returns regressed on weekly market returns)

e.g.0.67 × 0.329 + 0.33 = 0.550

termsβ (beta)

Period 2024-05-10–2026-11-04, using S&P 500 ETF (SPY) as the market proxy. Source: Yahoo Finance price history.

Cost of equity7.98%

formularisk-free rate + β × equity risk premium

e.g.5.0% + 0.55 × 5.5% = 8.0%

termsCAPM · Risk-free rate · β (beta) · Equity risk premium (market risk premium)

Market value of equity$21.63B

formulafiscal year-end closing price × shares outstanding (= market cap)

termsMarket capitalization · Market value of equity

Interest-bearing debt$1.93B
Cost of debt3.14%

formulainterest expense ÷ interest-bearing debt × 100 (clamped to 0–10%; falls back to the risk-free rate if there’s no debt)

termsInterest-bearing debt · Risk-free rate

Capital structure (equity weight : debt weight)92% : 8%

15

What the price implies (DCF)From SEC data

A company's value can be written as its free cash flow divided by (cost of capital − perpetual growth). Working that backwards from the market's valuation shows how much growth the share price assumed — compared here with the company's actual past growth.

Growth the price implies (price on 2026-11-04)

3.7%

Perpetual FCF growth: g = r − FCF ÷ EV = 7.5% − 3.8%

Past FCF growth (FY2021–FY2026)

+16.6%

Compound annual rate, 5 years

Past revenue growth (FY2021–FY2026)

+13.8%

Compound annual rate, 5 years

Inputs (FY2026): free cash flow $972M (operating CF − capex); enterprise value $25.33B = market cap $23.83B (latest close, 2026-11-04) + debt $1.93B − cash and short-term investments $440M; r = WACC of 7.5% using this page’s default assumptions (β 0.55, risk-free 5.0%, market premium 5.5%).

Three WACC scenarios

The same calculation under cautious, base and optimistic cost-of-capital assumptions (risk-free rate fixed at the 10-year Treasury yield). Pick one to load it into the sliders below.

Try your own assumptions

V = FCF ÷ (r − g). It starts at the implied growth rate, where the theoretical value equals today’s enterprise value.

Theoretical enterprise value

$25.59B

FCF $972M ÷ (7.5% − 3.7%)

Theoretical ÷ actual enterprise value

1.01x

Above 1x: these assumptions value the business above the market did

How sensitive the answer is

Theoretical ÷ actual enterprise value for each combination of r and g.

g \ r5.5%6.5%7.5%8.5%9.5%
0%0.70x0.59x0.51x0.45x0.40x
2%1.10x0.85x0.70x0.59x0.51x
4%2.56x1.54x1.10x0.85x0.70x
6%—7.68x2.56x1.54x1.10x
8%———7.68x2.56x

A simplified model for seeing what the market price assumes, not a forecast or a target price. It treats free cash flow as growing at one constant rate forever; the result swings widely with small changes in r and g, and is undefined when g reaches r. Free cash flow here is operating cash flow minus capex, which is after interest — a full DCF of enterprise value would use cash flow before interest. Market cap uses the latest close (2026-11-04) × shares at fiscal year-end; free cash flow and WACC inputs are from the latest fiscal year.

16

Earnings qualityFrom SEC dataShow

The same reported profit can mean different things depending on whether it's backed by cash, driven by the core business, or the result of a one-off item. Four checks below.

  • ✓

    Operating CF ÷ net income: averages 2.96x

    Profit is backed by cash coming in.

  • ✓

    Accrual ratio (latest): -5.4%

    A small share of profit rests on accounting estimates.

  • ✓

    Core-earnings share (operating income ÷ pretax income): 105%

    Most profit comes from core operations.

  • ✓

    Days sales outstanding: 72 → 66 days

    No major slowdown in collecting on sales.

Operating CF vs. net income

Unit: $M — operating CF above net income means profit is backed by cash

  • Operating CF
  • Net income

formulacash flow from operations ÷ net income attributable to the company

termsCash flow from operations (operating CF) · Net income (attributable to the company)

formula(net income − operating CF) ÷ average total assets × 100

termsNet income (attributable to the company) · Cash flow from operations (operating CF) · Total assets

Source: each period's Form 10-K (SEC EDGAR). Latest: filed 2026-05-29

Profit bridge (FY2026)

Unit: $M — what moved profit from operating income to net income

  • Profit (each stage)
  • Pushed profit up
  • Pushed profit down

formulaoperating income ÷ income before income taxes × 100

termsOperating income · Income before income taxes (pretax income)

Source: each period's Form 10-K (SEC EDGAR). Latest: filed 2026-05-29

Receivables & inventory days

Unit: days — days grow when receivables or inventory build up faster than sales

  • Days sales outstanding
  • Days inventory outstanding

formulaaverage receivables (opening + closing ÷ 2) ÷ revenue × 365

termsAccounts receivable · Revenue (net sales)

formulaaverage inventory (opening + closing ÷ 2) ÷ cost of revenue × 365

termsInventory · Cost of revenue (COGS)

Worked examples (latest period)

formulacash flow from operations ÷ net income attributable to the company

e.g.$1,341M ÷ $782M = 1.71x

termsCash flow from operations (operating CF) · Net income (attributable to the company)

formulaoperating income ÷ income before income taxes × 100

e.g.$1,102M ÷ $1,047M × 100 = 105%

termsOperating income · Income before income taxes (pretax income)

formulaaverage receivables (opening + closing ÷ 2) ÷ revenue × 365

e.g.($1,044M + $1,093M) ÷ 2 ÷ $5,936M × 365 = 66 days

termsAccounts receivable · Revenue (net sales)

formulaaverage inventory (opening + closing ÷ 2) ÷ cost of revenue × 365

e.g.($581M + $632M) ÷ 2 ÷ $3,309M × 365 = 67 days

termsInventory · Cost of revenue (COGS)

17

Who holds the sharesFrom SEC dataShow

How much of the stock large institutional investors report owning on SEC Form 13F, how much the directors and executive officers hold (and how much of the vote they control), and roughly how much is left for individual investors. Shown next to beta so the holder mix can be read alongside how much the stock swings.

Institutions, insiders and everyone else, 13F holdings as of 2026-06-30

“Everyone else” is what remains after shares reported on Form 13F and shares held by directors and executive officers: mostly individual investors, plus non-insider families or foundations and smaller or foreign institutions. The figures have different dates and 13F reports count some shares twice — read it as an approximate split.

Held by 13F filers
97.3%
Directors & officers (shares)
1.1%
Everyone else (est.)
1.6%

individuals and other non-13F holders

Directors & officers (voting power)
—

not stated in the proxy

Institutional-ownership rank
93 of 416

1 = most institutional; 22% of covered companies have more

Beta (adjusted)
0.55

above 1 = swings more than the market

  • 95.0M shares reported by 831 13F filers ÷ 97.6M shares outstanding on 2026-05-27. Option positions are excluded.
  • Directors and executive officers as a group, from the proxy statement’s beneficial-ownership table; includes shares they can acquire within 60 days. Directors and executive officers as a group held about 1.09M shares, including rights to acquire shares.
  • A large “everyone else” share can still reflect a family, trust or foundation stake held outside the board; check the proxy statement’s 5% holders.

Sources: SEC Form 13F data set (holdings as of 2026-06-30) · Form DEF 14A filed 2026-06-11 (beneficial ownership table) · Form 10-K cover page (shares outstanding as of 2026-05-27)

18

Strengths & weaknessesSite analysis

Strengths

  1. 1. Recurring revenue

    Service and consumables were 79% of FY2026 revenue.

    Evidence: Form 10-K (FY2026, year ended 2026-03-31)

  2. 2. Dividend record

    Raised the dividend each consecutive year since 2005.

    Evidence: Form 10-K (FY2026, year ended 2026-03-31)

  3. 3. Falling debt

    Debt fell to $1,932M.

    Evidence: Form 10-K (FY2026, year ended 2026-03-31)

Weaknesses

  1. 1. Past low earnings

    Net income fell to $107M in FY2023.

    Evidence: Form 10-K (FY2026, year ended 2026-03-31)

  2. 2. EO exposure

    Agreed to pay up to $48.2M to settle ethylene oxide claims.

    Evidence: Form 10-Q (quarter ended 2026-06-30)

19

What draws investors to itSite analysis

Why the stock can look attractive to investors — each point paired with what has to hold for it to stay true, and the opposing view. This is this site's analysis, not a recommendation to buy or sell.

P/E (FY2026)

27.9x

Price at fiscal year-end ÷ diluted EPS

Dividend yield (FY2026)

1.11%

Dividends per share ÷ fiscal year-end price

Payout ratio (FY2026)

31%

Dividends per share ÷ diluted EPS

FCF yield (FY2026)

4.5%

(Operating CF − capex) ÷ market cap

  1. 1. Recurring model

    Service revenue $2,876M.

    What has to hold
    Procedure volumes grow.
    The other side
    Hospital capital budgets.

    Evidence: Form 10-K (FY2026, year ended 2026-03-31)

  2. 2. Dividend growth

    Dividend per share rose from $1.57 to $2.46.

    What has to hold
    Cash flow stays strong.
    The other side
    Regulatory actions.

    Evidence: Form 10-K (FY2026, year ended 2026-03-31)

20

ResilienceSite analysisShow

How well the company could absorb a bad year: its financial buffer, how its revenue and profit held up in the worst year on record, and what the 10-K says about the business's exposure to shocks. Figures and filing statements only — no overall rating.

1. Financial buffer (FY2026)

Cash & short-term investments ÷ debt due within a year

3.7x

$440M vs. $119M

Interest coverage (operating income ÷ interest expense)

18.2x

$1.1B vs. $61M

Free cash flow ÷ dividends paid

4.0x

$972M vs. $242M (FCF = operating CF − capex)

2. Worst year in the record, and the recovery

FigureWorst year-over-year changeBack to the prior level?
RevenueNo decline in the record—
Operating income-12.9% in FY2022 ($548M → $478M)Yes, by FY2023

Covers only the 6 fiscal years on record (FY2021–FY2026), which may not include a full recession — the worst year here isn’t necessarily how the company would fare in a severe downturn.

3. Business resilience (from the 10-K)

  • 2021

    Net income $397M in FY2021.

    Source: Form 10-K (FY2026, year ended 2026-03-31)

22

Risks (including geopolitical)Site analysis

Starting from the 10-K's Risk Factors section, organized by category — geopolitical, currency, raw materials, regulatory, disaster, and more — with impact and likelihood assessed by this site.

Risk map

Vertical = impact on results, horizontal = likelihood. Upper right = most severe. Numbers match the list below (placement is this site’s own assessment).

Impact
High
1
Med
23
Low
45
LowMedHigh

Likelihood →

"Company disclosure" vs. "this site’s assessment"

The description and mitigation for each risk are this site’s summary of the 10-K’s "Risk Factors" section. Impact and likelihood are this site’s own assessment, not the company’s — where the company discloses its own likelihood assessment, that is noted in the summary.

Impact is judged from how large the affected business is relative to total revenue/profit, and from the risk’s track record of moving results in the past. Likelihood is judged from the filing’s wording and the current business environment (already occurring, or recurring). See the rating criteria.

  1. 1Law & regulation

    FDA enforcement

    Company disclosure (summarized from the 10-K)
    Inspections can lead to warning letters, consent decrees and sanctions.
    Company’s stated mitigation
    Not stated in the filings.
    This site’s assessment
    Impact High / Likelihood Med
  2. 2Law & regulation

    Ethylene oxide

    Company disclosure (summarized from the 10-K)
    EO-related litigation and regulation affect AST.
    Company’s stated mitigation
    Not stated in the filings.
    This site’s assessment
    Impact Med / Likelihood Med
  3. 3Competition & technology shift

    Competition

    Company disclosure (summarized from the 10-K)
    Competes with broad-line makers and Sterigenics in AST.
    Company’s stated mitigation
    Not stated in the filings.
    This site’s assessment
    Impact Med / Likelihood Med
  4. 4Law & regulation

    IRS notices

    Company disclosure (summarized from the 10-K)
    IRS assertions could mean about $50M of tax.
    Company’s stated mitigation
    Not stated in the filings.
    This site’s assessment
    Impact Low / Likelihood Med
  5. 5Supply chain

    Consolidation plan

    Company disclosure (summarized from the 10-K)
    Moves formulated chemistry production to North Carolina.
    Company’s stated mitigation
    Not stated in the filings.
    This site’s assessment
    Impact Low / Likelihood Med

23

What changed in the risk factorsFrom SEC data

Paragraphs in the latest 10-K's Risk Factors that have little overlap with the year before, and paragraphs that were dropped.

New or substantially reworded (6)

  • force. The U.S. has solicited feedback from the trading community regarding the operation of the USMCA, and the joint review could result in changes, including, for example, the processes by which goods qualify for preferential treatment, the tariffs applicable to products or other restrictions on the movement of goods within the region under the USMCA. Changes to the USMCA could adversely affect our manufacturing operations and those of our suppliers in Canada and Mexico and impact our ability to manufacture and market products or source materials at competitive prices, which could have a material adverse effect on our financial condition and results of operations. We cannot predict the ultimate scope, duration, or impact of current or future tariff measures, changes to existing trade agreements, such as the USMCA, or the imposition of other trade restrictions.

  • The introduction and evolution of climate- and sustainability-related laws, regulations and reporting requirements—many of which are not uniform across jurisdictions—can increase the complexity and cost of compliance and heighten our exposure to enforcement actions, litigation and reputational harm. For example, the European Union adopted the CSRD in 2023, and in 2025 the European Commission proposed amendments to the CSRD aimed at simplifying sustainability reporting in Europe. Such amendments entered into force in March 2026, with transposition into national law by EU member states required in 2027, while changes to the ESRS are expected to be finalized later in calendar year 2026. While the EU has adopted extensive requirements through CSRD and ESRS, which continue to evolve, other jurisdictions, including, for example, the United Kingdom and California, have their own sustainability…

  • Court of Cook County, Illinois. A claims process regarding confidential settlement agreements is ongoing and subject to final court approval. Read more

    Furthermore, some claims would be subject to further litigation if certain terms of the applicable settlement agreements are not fulfilled and we exercise our walkaway rights. Please refer to Note 12 to our consolidated financial statements titled “Commitments and Contingencies” for further information.

  • Similarly, we continue to invest in smart manufacturing to drive structural cost reduction in our facilities, including aligning work to more efficient manufacturing centers, implementing advanced manufacturing capabilities such as digital initiatives, automation and robots, and closing facilities that are not required to meet future capacity and work needs. Our success will depend on various factors, including our ability to either source or custom develop the necessary technology and components, and the digital transformation initiative’s cost-effectiveness, utility and competitive positioning. If our digital transformation initiative fails to develop as we expect, or progresses more slowly than expected, such failure to realize efficiencies and cost reduction benefits could adversely impact our financial condition and results of operations.

  • Likewise, governments and regulatory bodies worldwide are actively developing new laws, regulations and ethical guidelines governing AI use, including the European Union’s Artificial Intelligence Act. Read more

    Compliance with evolving and potentially inconsistent AI regulations across jurisdictions may be costly and complex. Failure to comply could result in significant penalties, restrictions on our use of AI, or reputational harm. The use of AI may also raise data privacy concerns, particularly if AI systems process sensitive health information subject to GDPR, HIPAA or other privacy regulations. If our competitors deploy AI technologies more effectively than we do, we may lose market share or be unable to maintain our competitive position. Failure to adequately manage AI-related risks could have a material adverse effect on our business, reputation, financial condition, and results of…

  • From time to time, we may invest in technology, business infrastructure, new businesses, product offerings and manufacturing innovations and expansion of existing businesses, each of which may require substantial cash investments and management attention. We believe cost-effective investments are essential to business growth and profitability; however, significant investments are subject to typical risks and uncertainties inherent in developing a new business or expanding an existing business. The failure of any significant investment to provide expected returns or profitability could have a material adverse effect on our financial results and divert management attention from more profitable business operations.

No longer in the text (4)

  • We might be adversely impacted by tax legislation or challenges to our tax positions.

  • The U.S. Tax Cuts and Jobs Act (the “TCJA”) was signed into law on December 22, 2017. Read more

    Guidance continues to be issued clarifying the application of this legislation and changes have been proposed, and in many instances finalized, with respect to a number of income tax provisions (including foreign tax credit regulations) in the U.S. that could increase our total tax expense. In addition, beginning January 1, 2022, the limitation on deductibility of interest expense, which generally limits a deduction for interest expense to 30% of taxable income (subject to certain adjustments), must be determined by reducing taxable income by depreciation and amortization deductions, which may limit our ability to deduct interest expense in the future. We cannot predict the overall impact that the additional guidance and recent changes may have on our business. In addition, due to the expiration of…

  • Although we are organized under the laws of Ireland and are a tax resident in Ireland for Irish tax purposes, the IRS may assert that we should be treated as a U.S. Read more

    corporation (and, therefore, a U.S. tax resident) for U.S. federal tax purposes pursuant to Section 7874 of the Code (“Section 7874”). For U.S. federal tax purposes, a company generally is considered to be a tax resident in the jurisdiction of its organization. Because we are organized under the laws of Ireland, we would generally be classified as a non-U.S. corporation (and, therefore, a non-U.S. tax resident) under these rules. Section 7874, however, provides an exception to this general rule under which a non-U.S. organized entity may be treated as a U.S. corporation for U.S. federal tax purposes. The rules under Section 7874 are complex, but as a general matter, a foreign corporation is treated as a U.S. corporation if…

  • For example, on January 5, 2023, the CSRD became effective. The CSRD expands the number of companies required to publicly report ESG-related information, defines the ESG-related information that companies are required to disclose in accordance with ESRS and imposes additional assurance obligations with respect to such disclosures. While CSRD rules are prescriptive for the types of data to be reported, the methodology for quantifying and qualifying such data are still developing and uncertain and may impose increased costs on us related to complying with our reporting obligations and increase risks of non-compliance with ESRS and the CSRD. In addition, there is currently uncertainty surrounding the requirements to publish ESG-related information under the CSRD and the content requirements of such report under the ESRS. On February 26, 2025, the European Commission proposed an “Omnibus”…

1 more paragraphs differ; the filings below have the full text.

Matched automatically, quoted as filed, and may include rewording of an existing risk. Compares Item 1A of the 10-K filed May 29, 2026 ↗ with the 10-K filed May 29, 2025 ↗.

24

What to watch going forwardSite analysis

  • North Carolina consolidation.
  • Service growth.
  • IRS Tax Court petitions.

25

Source documentsShow

This page's financial figures come from the Form 10-Ks listed below. Check the original filings for full detail.

Last updated

Analysis last edited: November 6, 2026 · Financial data fetched: November 4, 2026 15:27 (SEC EDGAR) · Source 10-K filed: May 29, 2026

Built on10-K FY2026 · filed 2026-05-29Proxy statement (2026)

Next update expectedAfter FY2027’s 10-K is filed (roughly 60–90 days after fiscal year end (sooner for larger filers)), financials and analysis will be refreshed.

This page is this site’s own analysis based on public information, and does not represent Steris’s views. It is not a recommendation to buy or sell any security, and this site does not guarantee the accuracy of any figure or statement here. Always verify against the original source documents before making an investment decision.